Merck, NanoBio ink RSV, flu deal; Incoming Princeton freshmen to be offered Novartis' Bexsero;

> Ann Arbor, MI-based NanoBio has signed a licensing agreement with Merck ($MRK) to produce an RSV vaccine and a flu vaccine. More

> About 1,300 incoming Princeton students will be eligible to receive Novartis' ($NVS) meningitis B vaccine Bexsero--unapproved in the U.S.--following an outbreak on campus last year. Report

> The GAVI Alliance has joined with UNICEF and WHO to offer a rotavirus vaccine in Cameroon. More

> Inovio Pharmaceuticals ($INO) has appointed E.J. Brandreth as VP of Quality. Release

> Researchers at Iowa State University have created the first heat-resistant "nanovaccines" to help vaccinate those in developing countries. Report

> The FDA has expanded the age indication for Sanofi's ($SNY) Tdap vaccine by one year to include 10-year-old children. Release

> WHO has declared the South-East Asia region polio-free. Announcement

> Takeda has won Japanese approval for two pandemic flu vaccines. More

And Finally... Merck is using cloud-based computing to speed up vaccine data analysis for faster development. More

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.